Compare GSK plc (GSK) vs HSBC Holdings plc (HSBC) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

HSBC trades at $100.72, up 1.48% today, near its 52-week high. Technical indicators show a bullish trend with support at $100 and resistance at $101. The company reported $22.29B net income for 2025 with a 30.81% net margin, though Q1 2026 EPS missed expectations. Recent news highlights strategic moves including a potential Turkey business sale and AI partnerships.

The outlook is cautiously optimistic with strong profitability and analyst buy ratings (38.1%), but risks include execution of global restructuring and regulatory penalties. Earnings growth and strategic focus on core markets are key catalysts for upside.